Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 75 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

13 trials in Phase 3/4

Results Transparency

0%

0 of 45 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 1
56(74.7%)
Phase 3
12(16.0%)
Phase 2
6(8.0%)
Phase 4
1(1.3%)
75Total
Phase 1(56)
Phase 3(12)
Phase 2(6)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (75)

Showing 20 of 75 trials
NCT07516899Phase 1Not Yet Recruiting

Mass Balance Study of [14C] LPM3770164 in Healthy Participants

Role: lead

NCT07396870Phase 2Not Yet Recruiting

A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia

Role: lead

NCT07391566Phase 1Not Yet Recruiting

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Role: lead

NCT07371065Phase 1Enrolling By Invitation

To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects

Role: lead

NCT07292233Phase 1Active Not Recruiting

A Food Effect Study of LY03020 in Healthy Subjects

Role: lead

NCT07230652Phase 1Recruiting

A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020

Role: lead

NCT07236476Phase 2Active Not Recruiting

Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

Role: lead

NCT06556966Phase 1Completed

A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects

Role: lead

NCT06980207Phase 1Not Yet Recruiting

A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

Role: lead

NCT06793995Phase 1Not Yet Recruiting

Effect of Food and Age on the Pharmacokinetics of LY03017

Role: lead

NCT06731868Phase 1Recruiting

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

Role: lead

NCT06474650Phase 1Completed

Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets

Role: lead

NCT06216054Phase 1Completed

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

Role: lead

NCT06496048Phase 3Recruiting

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Role: lead

NCT06467409Phase 2Recruiting

Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic Surgery

Role: lead

NCT04638491Phase 1Completed

Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

Role: lead

NCT06426485Phase 4Not Yet Recruiting

To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

Role: lead

NCT06247410Phase 2Completed

Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease

Role: collaborator

NCT06388551Phase 1Not Yet Recruiting

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017

Role: lead

NCT05853354Phase 3Active Not Recruiting

Comparative Efficacy, Safety, PK, and Immunogenicity Study

Role: lead